Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling

Institute of Pathology, University of Wuerzburg, Josef-Schneider-Strasse 2, Wuerzburg, Germany.
Blood (Impact Factor: 9.78). 08/2010; 116(6):953-61. DOI: 10.1182/blood-2010-01-263806
Source: PubMed

ABSTRACT The genome of mantle cell lymphoma (MCL) is, in addition to the translocation t(11;14), characterized by a high number of secondary chromosomal gains and losses that probably account for the various survival times of MCL patients. We investigated 77 primary MCL tumors with available clinical information using high-resolution RNA expression and genomic profiling and applied our recently developed gene expression and dosage integrator algorithm to identify novel genes and pathways that may be of relevance for the pathobiology of MCL. We show that copy number neutral loss of heterozygosity is common in MCL and targets regions that are frequently affected by deletions. The molecular consequences of genomic copy number changes appear complex, even in genomic loci with identified tumor suppressors, such as the region 9p21 containing the CDKN2A locus. Moreover, the deregulation of novel genes, such as CUL4A, ING1, and MCPH1, may affect the 2 crucial pathogenetic mechanisms in MCL, the disturbance of the proliferation, and DNA damage response pathways. Deregulation of the Hippo pathway may have a pathogenetic role in MCL because decreased expression of its members MOBKL2A, MOBKL2B, and LATS2 was associated with inferior outcome, including an independent validation series of 32 MCLs.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-Hodgkin lymphomas (NHLs) include any kind of lymphoma except Hodgkin's lymphoma. Mantle cell lymphoma (MCL) is a B-cell NHL and it accounts for about 6% of all NHL cases. Its epidemiologic and clinical features, as well as biomarkers, can differ from those of other NHL subtypes. This article first provides a very brief description of MCL's epidemiology and clinical features. For etiology and prognosis separately, we review clinical, environmental, and molecular risk factors that have been suggested in the literature. Among a large number of potential risk factors, only a few have been independently validated, and their clinical utilization has been limited. More data need to be accumulated and effectively analyzed before clinically useful risk factors can be identified and used for prevention, diagnosis, prediction of prognosis path, and treatment selection.
    Expert Review of Hematology 02/2014; DOI:10.1586/17474086.2014.889561 · 2.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we define the genetic landscape of mantle cell lymphoma through exome sequencing of 56 cases of mantle cell lymphoma. We identified recurrent mutations in ATM, CCND1, MLL2 and TP53. We further identified a number of novel genes recurrently mutated in patients with mantle cell lymphoma including RB1, WHSC1, POT1, and SMARCA4. We noted that mantle cell lymphomas have a distinct mutational profile compared to lymphomas from other B-cell stages. The ENCODE project has defined the chromatin structure of many cell types. However, a similar characterization of primary human mature B cells has been lacking. We defined, for the first time, the chromatin structure of primary human naïve, germinal center and memory B cells through chromatin immunoprecipitation and sequencing (ChIP-seq) for H3K4me1, H3K4me3, H3Ac, H3K36me3, H3K27me3 and PolII). We found that somatic mutations that occur more frequently in either mantle cell lymphomas or Burkitt lymphomas were associated with open chromatin in their respective B cells of origin, naïve B cells and germinal center B cells. Our work thus elucidates the landscape of gene-coding mutations in mantle cell lymphoma and the critical interplay between epigenetic alterations associated with B cell differentiation and the acquisition of somatic mutations in cancer.
    Blood 03/2014; 123(19). DOI:10.1182/blood-2013-07-517177 · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Telomere shortening is of pathogenic and prognostic importance in cancers. Here we analyzed telomere length in 73 mantle cell lymphoma (MCL), 55 chronic lymphocytic leukemia (CLL) and 20 normal B-cell samples using quantitative PCR (Q-PCR) to study its association with disease characteristics as well as outcome. Telomere length was found highly variable in MCL (range 2.2-13.8 kb, median 4.3 kb). Telomere dysfunction in MCL was evident from comparison with normal B-cells (median 7.5 kb) but had no significant association with any biological or clinical feature. This was in contrast to CLL, where a significant correlation of short telomeres with poor prognostic subgroups was confirmed. There was a trend towards an increased number of genomic aberrations with shortening of telomeres in MCL. No difference in survival was observed between the groups with short and long telomeres, indicating that, as opposed to CLL, telomere length is not of prognostic relevance in MCL.
    Blood 12/2012; 121(7). DOI:10.1182/blood-2012-08-452649 · 9.78 Impact Factor